Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human interferon alfa-2a suppository for cervical HPV infection
ChiCTR2100043961Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of interferon alfa-2a in cervical human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (4 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Cervical HPV detection. Started Feb 2021; status: recruiting.
02
Drugs
interferon alfa-2a
03
Conditions
cervical human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on ChiCTR2100043961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043961.